BIOSTAR PHARM-B (02563) has announced that its application to the Listing Committee of The Stock Exchange of Hong Kong Limited for the listing of and permission to deal in 148 million H shares, converted from an equivalent number of non-listed shares, has been approved. The board of directors is pleased to announce that the approval was granted on March 20, 2026.